Increases sexual desire in both men and women
Improves erectile function
PT-141, also known as bremelanotide, is a synthetic peptide that works similarly to the natural hormone melanocortin. It is FDA- approved to treat hypoactive sexual desire disorder (low sex drive) in premenopausal women. It is also used to treat low libido and erectile dysfunction in men.
The beneficial effect of PT-141 on sexual activity in men and women was discovered by accident. Initially, the drug was explored as a way to increase skin pigmentation. Its ability to increase sexual desire was an unexpected side-effect.
PT-141 is available as a subcutaneous injection and as a nasal spray. Clinical trials have shown that peptides pass from the nasal cavity to the brain.
Hypoactive sexual desire disorder is not uncommon. It affects 8.9% of women between the ages of 18 and 44, 12.3% of women between the ages of 45 to 64, and 7.4% of women over the age of 65. Low sexual desire tends to increase with age, but distress associated with the disorder decreases, which means that the condition’s prevalence is consistent across ages. Low sexual desire is linked with lower health-related quality of life, lower overall happiness, and a higher risk of anxiety and depression.
Female sexual dysfunction is a constellation of symptoms, including decreased desire, interest, arousal, orgasm, or pain with sex. Two large clinical trials demonstrated PT-141 safety and efficacy. Women using bremelanotide had a statistically significant improved sexual desire. Unlike previous treatment options, bremelanotide (PT-141) does not interact with alcohol.
PT-141 appears to act on melanocortin receptors 3 and 4 in the brain. It enhances sexual arousal and penile erections by releasing dopamine, a neurotransmitter in the brain.
In a double-blinded placebo-controlled study, approximately 80 percent of men developed an erection satisfactory for intercourse after using PT-141 whether the cause of ED was physical or psychological, and 68 percent of men reported an increase in sexual desire.
Clinical trials are underway to further investigate PT-141; early results show that PT-141 is effective for men with diabetes and ED and for men who do not respond well to oral ED medications.
PT-141 (bremelanotide) is a nonselective agonist of the melanocortin receptors type 3 and 4, which means that it binds to these receptors and induces a similar effect to when natural peptides bind to these receptors. It is the active metabolite of Melanotan II.
In the brain, PT-141 influences sexual behavior by stimulating dopamine release from the medial preoptic area in the brain, an area of the brain associated with sexual behavior.
PT-141 acts in the brain where it can induce penile erections and increase libido. Traditional oral ED meds act on blood vessels.
Traditional oral ED medications increase nitric oxide levels in blood vessels, increasing blood flow into the penis. The neurons in the parasympathetic nervous system trigger the release of nitric oxide from the inner lining of blood vessels, causing the blood vessels to dilate and the smooth muscle lining the corpora cavernosa in the penis to relax. Blood flows into the corpora cavernosa, increasing pressure within the penis and causing an erection.
Nitric oxide causes a cascade of chemical reactions to increase blood flow into the penis. The enzyme phosphodiesterase class 5 (PDE5) inhibits these reactions. Oral ED medications block PDE5.
PT-141 should not be taken in conjunction with other ED meds as it may increase the risk of priapism, a prolonged erection that can damage the penis if untreated.
PT-141 is a melanocortin receptor agonist that is FDA-approved to treat female sexual desire disorder, a cluster of symptoms that affects about 10% of women. PT-141 is also an effective ED treatment option that boosts libido in men with and without ED, regardless of whether the cause of ED is physical or psychological.
The consultation with the doctor is included for free.
Patients have access to the medical staff throughout the duration of the treatment plan.
Shopping around to find out where to buy PT-141 with all of the needed supplies? We inlcude all necessary supplies your treatment plan.
With the convenience and speed of online shopping, it’s not surprising why many people consider Invigor Medical as among the best places to buy PT-141
Invigor Medical is partnered with the best PT-141 suppliers in the US. Our Licensed pharmacies provide top quality medications tested for purity and potency.
No Surprises! Pay one price for your service, everything included.
PT-141 stimulates melanocortin receptors in the brain in an area of the brain that affects sexual behavior. It increases libido in men and women and improves erectile function in men. PT-141 is also used to treat female sexual arousal disorder.
PT-141 is a prescription medication. If you are interested in PT-141, you will be asked to complete medical forms on the secure Invigor Medical platform. After completing these forms, you will meet with an Invigor Medical healthcare professional. If you have no contraindications to using PT-141, they will prescribe it and arrange for it to be delivered from one of our partner pharmacies.
PT-141 was developed from the Melanotan II peptide. When researchers explored the use of this peptide as a tanning agent, they noted an unusual side effect—increased libido and spontaneous erections. While it still promotes skin tanning, PT-141 is prescribed for its other effects: improving libido in men and women, improving erectile function, and treating hypoactive sexual arousal disorder.
PT-141 is injected just under the skin in fatty tissue, typically the skin on the lower right side of the abdomen. PT-141 is injected at least 45 minutes before sexual activity.
PT-141 is also available as a nasal spray.
PT-141 is currently FDA-approved to treat female hypoactive sexual desire disorder in premenopausal women. PT-141 is also used to treat decreased libido in men and women and erectile dysfunction in men.
Female arousal disorder or female hypoactive sexual desire disorder describes a condition in which women have little or no interest in sex. Women with this condition do not respond psychologically or physically to sexual stimulation. It is only considered a medical condition if the affected woman is distressed by the lack of arousal.
Based on DSM-5 criteria, sexual arousal disorder can be diagnosed when there is a decrease in three or more of the following:
Yes, PT-141 (bremelanotide) is a synthetic analogue of melanocyte-stimulating hormone and is the active metabolite of Melanotan 2.
Clinical trials have demonstrated the safety and effectiveness of combining PT-141 and sildenafil (Viagra). Investigators found that the combination (PT-141 and sildenafil) significantly increased erectile activity when compared to either drug used alone. Using PT-141 and sildenafil together did not cause any new side effects or increase the frequency of side effects when compared to using only one of the drugs.